SPECIALTY GUIDELINE MANAGEMENT

LUMOXITI (moxetumomab pasudotox-tdfk)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

A. FDA-Approved Indication

Lumoxiti is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA).

Limitations of use

Lumoxiti is not recommended in patients with severe renal impairment (CrCl≤29 mL/min).

B. <u>Compendial Uses</u>

Hairy cell leukemia

All other indications are considered experimental/investigational and not medically necessary.

II. CRITERIA FOR INITIAL APPROVAL

Hairy Cell Leukemia

Authorization of 6 months may be granted for treatment of relapsed or refractory hairy cell leukemia as a single agent when all of the following criteria are met:

- A. Member has received at least two prior systemic therapies, including treatment with a purine nucleoside analog.
- B. Member has not previously received 6 or more cycles of treatment with the requested medication.

III. CONTINUATION OF THERAPY

Authorization of up to 6 months may be granted for continued treatment in members requesting reauthorization for an indication listed in Section II when all of the following criteria are met:

- A. Member will receive a maximum of 6 cycles with the requested medication.
- B. There is no evidence of disease progression or an unacceptable toxicity while on the current regimen.

IV. REFERENCES

- 1. Lumoxiti [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; February 2022.
- 2. The NCCN Drugs & Biologics Compendium 2022 National Comprehensive Cancer Network, Inc. http://www.nccn.org. Accessed May 31, 2022.

Lumoxiti 2739-A SGM P2022.docx

© 2022 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

